🇺🇸 FDA
Patent

US 10632173

Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

granted A61KA61K38/1703A61K38/1709

Quick answer

US patent 10632173 (Formulations and methods of use for alpha connexin C-terminal (ACT) peptides) held by FIRSTRING RESEARCH, INC. expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
FIRSTRING RESEARCH, INC.
Grant date
Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/1703, A61K38/1709, A61K38/1767, A61K38/177